Safety And Efficacy Of Ab-Interno Canaloplasty With Using The Itrack Advance In Open-Angle Glaucoma – 2-Year Results

To evaluate the safety and effectiveness of ab-interno canaloplasty using a new canaloplasty device (iTrack Advance, Nova Eye Medical, Fremont, USA) in reducing intraocular pressure (IOP) and medication burden in open-angle glaucoma.

Single-center study conducted at an ophthalmology clinic in Germany.

This retrospective case series included patients with primary open-angle glaucoma (POAG) or pseudoexfoliative glaucoma (PEX) who underwent ab-interno canaloplasty with the iTrack Advance, either as a standalone procedure or combined with phacoemulsification. Primary outcomes were IOP and medication use at 12, 18, and 24 months postoperatively. Safety outcomes included intraoperative and postoperative complications.

94 eyes (mean age: 71.2±7 years) were included. Mean IOP (mmHg) decreased from 18.4±4.4 at baseline to 14.2±3.1 at 12M (n=90; p<0.001), 13.9±3.2 at 18M (n=61; p<0.001), and 14.2±2.9 at 24M (n=39; p<0.001). Mean medication use decreased from 1.9±0.8 at baseline to 0.1±0.5 at 12M and 18M (p<0.001) and 0.2±0.6 at 24M (p<0.001). Visual field mean deviation remained stable (p=0.498). In eyes with preoperative uncontrolled glaucoma (IOP>18mmHg; n=46), IOP decreased from 21.8±3.1 to 15.7±2.5 at 12M (n=42; p<0.001), with medication use decreasing from 1.9±0.8 to 0.1±0.8; 40 of those 42 eyes were meds-free at 12M, compared to none preoperatively. No sight-threatening complications were observed and no additional glaucoma procedures were required.

Ab-interno canaloplasty with the iTrack Advance demonstrated a favorable safety profile and provided significant, sustained reductions in IOP and medication use in patients with open-angle glaucoma up to 24 months postoperatively.